Ribosomal protein L17 pseudogene 23 (RPL17P23)

RPL17P23 (ribosomal protein L17 pseudogene 23) is a non-coding pseudogene in the human genome, related by sequence similarity to the ribosomal protein L17 (RPL17), which is a structural component of the 60S ribosomal subunit required for protein synthesis[1][5]. Pseudogenes like RPL17P23 arise from duplication or retrotransposition events and do not encode active protein products. While some pseudogenes have emerging roles as gene regulators or disease modifiers, RPL17P23 does not have established biological or pathological functions. There is no evidence that it is a therapeutic target or involved in direct disease mechanisms. It is sometimes referenced in genomic annotation studies but is largely considered of limited functional significance in most biomedical contexts[1][5]. Key clarification: - RPL17P23 should not be confused with the functional ribosomal protein L17 (RPL17), which is a structural ribosomal protein and has been implicated in biological processes such as stress vulnerability, depression, and ribosomopathies[7][4]. - Pseudogenes like RPL17P23 are generally excluded from drug target lists and clinical databases due to their lack of protein-coding and direct biochemical activity[1][5].

Other names

RPL17_15_751RPL17P23

None. There are no drugs targeting this pseudogene, thus no mechanism of action is described.